A Variant in a MicroRNA complementary site in the 3′ UTR of the KIT oncogene increases risk of acral melanoma
Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidhaas JB, Slack FJ. A Variant in a MicroRNA complementary site in the 3′ UTR of the KIT oncogene increases risk of acral melanoma. Oncogene 2010, 30: 1542-1550. PMID: 21119596, PMCID: PMC3069149, DOI: 10.1038/onc.2010.536.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsCase-Control StudiesHumansMelanomaMicroRNAsOncogenesProtein BiosynthesisProto-Oncogene Proteins c-kitRiskRNA, MessengerSkin NeoplasmsConceptsMessenger RNAsComplementary sitesNovel genetic markersKIT oncogeneTarget genesRegulatory relationshipsUntranslated regionGenetic markersHeritable riskFunctional variantsGenetic variantsOncogeneMultifaceted roleProtein levelsProtein expressionVariant resultsComplementary sequencesReporter dataUTRMelanoma pathogenesisMiR-221KIT variantsSeed regionExpressionVariantsA phase 2 trial of dasatinib in advanced melanoma
Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2010, 117: 2202-2208. PMID: 21523734, PMCID: PMC3116034, DOI: 10.1002/cncr.25766.Peer-Reviewed Original ResearchConceptsProgression-free survivalC-kit mutationsPhase 2 trialResponse ratePartial responseMedian progression-free survivalMelanoma cell proliferationDaily dasatinibMucosal primaryPFS ratesStarting dosageCommon toxicitiesUnresectable melanomaAdvanced melanomaPleural effusionMelanoma patientsPredictive biomarkersMinor responseCombination trialsTumor assessmentDose reductionPatientsPrespecified endpointsDasatinibMelanoma